Press release
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growing Rapidly by - Illumina Inc., Guardant Health Inc., APIS Assay Technologies Ltd., Gencurix Inc., RainSure Scientific.
Get a Free Sample Research PDF - https://datamintelligence.com/download-sample/esr1-mutated-metastatic-breast-cancer-diagnostics-market
The ESR1 Mutated Metastatic Breast Cancer Diagnostics market report majorly focuses on market trends, historical growth rates, technologies, and the changing investment structure. Additionally, the report shows the latest market insights, increasing growth opportunities, business strategies, and growth plans adopted by major players. Moreover, it contains an analysis of current market dynamics, future developments, and Porter's Five Forces Analysis.
ESR1 mutated metastatic breast cancer refers to a specific subtype of breast cancer where mutations occur in the ESR1 gene. This gene encodes for the estrogen receptor alpha (ERα), a key protein involved in estrogen signaling pathways within breast cells. Mutations in ESR1 can emerge during the course of breast cancer treatment, particularly in the metastatic stage. These mutations are linked to acquired resistance to hormonal therapies, including medications like tamoxifen and aromatase inhibitors. These therapies are designed to block estrogen receptor signaling, but ESR1 mutations can reduce their effectiveness, leading to challenges in managing metastatic breast cancer and requiring alternative treatment strategies.
Forecast Growth Projected:
The Global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2030. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.
List of the Key Players in the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Illumina Inc., Guardant Health Inc., APIS Assay Technologies Ltd., Gencurix Inc., RainSure Scientific, NeoGenomics Inc., Sysmex Corporation, Asuragen Inc., CUSABIO TECHNOLOGY LLC and Cayman Chemical Company among others.
Segment Covered in the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market:
By Test Type: NGS Based, PCR Based.
By Sample Type: Tissue, Plasma.
By End User: Oncology Centers, Diagnostic Centers, Cancer Research Institutes.
Regional Analysis:
The global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.
Get Customization in the report as per your requierments: https://datamintelligence.com/customize/esr1-mutated-metastatic-breast-cancer-diagnostics-market
Regional Analysis:
The global ESR1 Mutated Metastatic Breast Cancer Diagnostics Market report focuses on six major regions: North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa. The report offers detailed insight into new product launches, new technology evolutions, innovative services, and ongoing R&D. The report discusses a qualitative and quantitative market analysis, including PEST analysis, SWOT analysis, and Porter's five force analysis. The ESR1 Mutated Metastatic Breast Cancer Diagnostics Market report also provides fundamental details such as raw material sources, distribution networks, methodologies, production capacities, industry supply chain, and product specifications.
Chapter Outline:
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: key insights, key emerging trends, etc.
Chapter 3: Manufacturers competitive analysis, detailed analysis of ESR1 Mutated Metastatic Breast Cancer Diagnostics manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 5 & 6: Revenue of ESR1 Mutated Metastatic Breast Cancer Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: The main points and conclusions of the report.
Get a Free Sample PDF copy of the report @ https://datamintelligence.com/download-sample/esr1-mutated-metastatic-breast-cancer-diagnostics-market
FAQs
How big is the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market?
The ESR1 Mutated Metastatic Breast Cancer Diagnostics Market size was USD $$$ 2023. It is expected to reach USD $$$ 2031.
How fast is the ESR1 Mutated Metastatic Breast Cancer Diagnostics Market growing?
The ESR1 Mutated Metastatic Breast Cancer Diagnostics Market will exhibit a HIGH CAGR during the forecast period, 2023-2031.
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growing Rapidly by - Illumina Inc., Guardant Health Inc., APIS Assay Technologies Ltd., Gencurix Inc., RainSure Scientific. here
News-ID: 3576198 • Views: …
More Releases from DataM Intelligence 4Market Research
United States Skin Cancer Drugs Market Set to Surge: Innovative Therapies and Ri …
Market Overview:
The Skin Cancer Drugs Market is estimated to reach at a CAGR of 10.2% during the forecast period (2024-2031).
The Skin Cancer Drugs Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay ahead of the competition. Through a combination of qualitative and quantitative research…
United States Aircraft Battery Charger Market is expected to reach US$ 1032.9 Mi …
Market Size and Forecast:
The Global Aircraft Battery Charger Market Size reached US$ 570.5 million in 2022 and is expected to reach US$ 1032.9 million by 2030, growing with a CAGR of 7.9% during the forecast period 2024-2031.
The Aircraft Battery Charger Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to…
United States Cloud-based Printing Market is expected to reach US$ 3.96 billion …
Market Size and Forecast:
The Cloud-based Printing Market Size reached US$1.52 billion in 2024 and is expected to reach US$3.96 billion by 2032, growing with a CAGR of 12.71% during the forecast period 2025-2032.
The Cloud-based Printing Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM Intelligence empowers businesses to make informed decisions and stay…
United States Beauty Devices for At-Home Laser Treatments Market is expected to …
Market Size and Forecast:
The Global Beauty Devices for At-Home Laser Treatments Market Size reached US$537.1 million in 2024 and is expected to reach US$1,302.5 million by 2033, growing at a CAGR of 10.3% during the forecast period 2025-2033.
The Beauty Devices for At-Home Laser Treatments Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to delivering actionable intelligence, DataM…
More Releases for ESR1
FDA Approves INLURIYO (Imlunestrant): A Game-Changer for ESR1-Mutated Metastatic …
The pharmaceutical landscape for metastatic breast cancer treatment has witnessed a significant milestone with the FDA approval of INLURIYO (imlunestrant) on September 25, 2025. Eli Lilly's innovative, world-first oral selective estrogen receptor degrader (SERD) represents the first endocrine therapy innovation specifically targeting ESR1 mutations in over two decades, addressing a critical unmet medical need in estrogen receptor-positive (ER+), HER2-negative breast cancer patients.
Image: https://www.abnewswire.com/upload/2025/09/ccb2e17e2f3a2721c027dabdf0f1bd92.jpg
The pharmaceutical landscape for metastatic breast cancer treatment…
ESR1-Mutated Metastatic Breast Cancer Market Set for Significant Growth by 2034, …
DelveInsight's "ESR1 Mutated Metastatic Breast Cancer - Market Insight, Epidemiology And Market Forecast - 2034" [https://www.delveinsight.com/report-store/esr1-mutated-metastatic-breast-cancer-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=xpr] report delivers comprehensive insights into the disease landscape, historical and forecasted epidemiology, as well as ESR1 Mutated Metastatic Breast Cancer market trends across the 7MM (United States, EU4 [Germany, France, Italy, and Spain], United Kingdom, and Japan). The report reveals that the ESR1-mutated metastatic breast cancer market, valued at approximately USD 1.3 billion in…
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Size to Hit USD 93.21 M …
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market: Overview
The ESR1 mutated metastatic breast cancer diagnostics market is a rapidly evolving and specialized segment within oncology diagnostics, focusing on identifying mutations in the estrogen receptor gene (ESR1) that are closely linked to resistance against endocrine therapies in hormone receptor-positive (HR+) metastatic breast cancer. These mutations present significant clinical challenges by reducing the effectiveness of standard treatments. As precision medicine advances in oncology,…
ESR1-Mutated Metastatic Breast Cancer Market Industry Analysis by Size, Share, G …
Introduction
The ESR1-Mutated Metastatic Breast Cancer Market focuses on a specific subtype of hormone receptor-positive (HR+), HER2-negative metastatic breast cancer characterized by mutations in the estrogen receptor 1 (ESR1) gene. These mutations confer resistance to standard endocrine therapies such as aromatase inhibitors, making the disease more difficult to manage and highlighting the need for novel targeted approaches.
In recent years, the emergence of oral selective estrogen receptor degraders (SERDs), next-generation endocrine therapies,…
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market Growth Drivers, Forecas …
ESR1 Mutated Metastatic Breast Cancer Diagnostics Market report, published by DataM Intelligence, delivers detailed insights and analysis on major market trends, growth prospects, and emerging challenges. With a strong focus on providing actionable intelligence, DataM Intelligence enables businesses to make well-informed decisions and maintain a competitive edge. By blending both qualitative and quantitative research approaches, the company offers thorough reports that support clients in navigating complex market environments, driving strategic…
ESR1-Mutated Metastatic Breast Cancer Market Set for Significant Growth by 2034, …
The ESR1-mutated metastatic breast cancer market is witnessing a robust growth trajectory. Key breast cancer companies, including AstraZeneca, Olema Pharmaceuticals, Arvinas, Sermonix Pharmaceuticals, Roche, Eli Lilly and Company, H3 Biomedicine, Eisai, Pfizer, Sun Pharma Advanced Research Company, Zenopharm, Daiichi Sankyo, and others, are actively developing innovative treatment options for this specific patient population.
DelveInsight's "ESR1 Mutated Metastatic Breast Cancer - Market Insight, Epidemiology And Market Forecast - 2034 [https://www.delveinsight.com/report-store/esr1-mutated-metastatic-breast-cancer-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report delivers…
